Aperiomics is a groundbreaking company revolutionizing the identification of infections globally. Utilizing Deep Shotgun Metagenomic Sequencing, it identifies over 37,000 microbes, including bacteria, virus, fungus, and parasite, offering a comprehensive solution that traditional tests lack. This not only improves diagnostic accuracy but also enhances the likelihood of positive clinical outcomes for patients who have been suffering from undiagnosed illnesses for years. The company's accolades, which include being named the Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018, showcase its significant success in the field.
Founded in 2013, Aperiomics operates in the Biotechnology and Health Care industries. The recent $360.00K Convertible Note investment from Tamiami Angels Fund in 14 December 2020 further validates its position as a promising venture for potential investors and highlights confidence from the investor community in the company's innovative approach and potential for future growth.
